Los Angeles Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Los Angeles Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-980	Closed	-$438K	–	1393
2021 Q3	$438K	Sell	980 -1,880	-66%	-$674K	﹤0.01%	1116
2021 Q2	$1.11M	Sell	2,860 -176	-6%	-$62.8K	﹤0.01%	811
2021 Q1	$1.09M	Buy	3,036 +1,003	+49%	+$443K	﹤0.01%	856
2020 Q4	$998K	Buy	2,033 +235	+13%	+$108K	﹤0.01%	948
2020 Q3	$583K	Buy	1,798 +54	+3%	+$18.4K	﹤0.01%	1023
2020 Q2	$635K	Buy	1,744 +1,286	+281%	+$325K	﹤0.01%	1020
2020 Q1	$97K	Buy	+458	New	+$145K	﹤0.01%	1298

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Los Angeles Capital Management's ATRA Position: Q4 2021 in Review

Los Angeles Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 980 shares — an estimated $438K sold.

Los Angeles Capital Management first reported a position in ATRA in Q1 2020 and held it in 7 quarters. The position peaked at $1.11M in Q2 2021. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

Los Angeles Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
Los Angeles Capital Management sold 980 Atara Biotherapeutics shares in Q4 2021, an estimated $438K.
Los Angeles Capital Management first reported a position in Atara Biotherapeutics in Q1 2020 and held it in 7 quarters.
Los Angeles Capital Management's Atara Biotherapeutics position peaked at $1.11M in Q2 2021.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.